Skip to main content
Log in

Non-alcoholic steatohepatitis has high cost burden in USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2017 US dollars

Reference

  • Younossi ZM, et al. Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States. Hepatology : 4 Sep 2018. Available from: URL: http://doi.org/10.1002/hep.30254

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Non-alcoholic steatohepatitis has high cost burden in USA. PharmacoEcon Outcomes News 813, 20 (2018). https://doi.org/10.1007/s40274-018-5327-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5327-y

Navigation